Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…Abstract Number: 0804 • ACR Convergence 2022
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Background/Purpose: China remains a high-burden country of both rheumatic disease (RD) and tuberculosis (TB) till today. Patients with RD are considered as a high-risk population…Abstract Number: 1545 • ACR Convergence 2022
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
Background/Purpose: Neutrophils are important in host defense. However, neutrophil activation has also been involved in the immunopathogenesis of several autoimmune diseases due to their many…Abstract Number: 0826 • ACR Convergence 2022
Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database
Background/Purpose: Adult Still's disease (ASD), including adult-onset Still's disease and carry-over systemic juvenile idiopathic arthritis (sJIA), is treated with glucocorticoids (GC) with or without immunosuppressive…Abstract Number: 1549 • ACR Convergence 2022
Toward Safer Glucocorticoid Therapy
Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…Abstract Number: 0831 • ACR Convergence 2022
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…Abstract Number: 1620 • ACR Convergence 2022
Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for…Abstract Number: 0863 • ACR Convergence 2022
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…Abstract Number: 0955 • ACR Convergence 2022
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge…Abstract Number: 1987 • ACR Convergence 2022
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…Abstract Number: 0960 • ACR Convergence 2022
Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus
Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy…Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…Abstract Number: 0128 • ACR Convergence 2022
Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
Background/Purpose: Alternate-day glucocorticoid (GC) treatment is an effective treatment option that can reduce GC-associated adverse events in patients with rheumatoid arthritis and other autoimmune rheumatic…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 22
- Next Page »